Literature DB >> 20505956

Antiemetic therapy for multiple-day chemotherapy and additional topics consisting of rescue antiemetics and high-dose chemotherapy with stem cell transplant: review and consensus statement.

Lawrence H Einhorn1, Steven M Grunberg, Bernardo Rapoport, Cynthia Rittenberg, Petra Feyer.   

Abstract

This paper will evaluate various topics related to chemotherapy-induced nausea and vomiting. The results published reflect a consensus conference convened in Perugia, Italy. The topics discussed include antiemetic therapy of multiple-day chemotherapy, high-dose chemotherapy, and rescue antiemetics.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20505956     DOI： 10.1007/s00520-010-0920-z

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


  12 in total

1.  Obstacles to managing chemotherapy-induced nausea and vomiting in high-dose chemotherapy with stem cell transplant.

Authors:  Andrea Tendas; Fabio Sollazzo; Antonio Bruno; Luca Cupelli; Pasquale Niscola; Adriana Concetta Pignatelli; Teresa Dentamaro; Paolo de Fabritiis; William Arcese
Journal:  Support Care Cancer       Date:  2012-02-19       Impact factor: 3.603

2.  Response.

Authors:  Emily S Van Laar; Jayashri Mehta Desai; Aminah Jatoi
Journal:  Support Care Cancer       Date:  2015-05-15       Impact factor: 3.603

3.  Chemotherapy induced nausea and vomiting in bone marrow transplant: the unmet need.

Authors:  Andrea Tendas; Pasquale Niscola; Alessio Perrotti; Teresa Dentamaro; Paolo de Fabritiis; William Arcese
Journal:  Support Care Cancer       Date:  2015-03-28       Impact factor: 3.603

4.  SEOM guide to antiemetic prophylaxis in cancer patients treated with chemotherapy 2013.

Authors:  J García Gómez; M E Pérez López; M Alonso Bermejo; Y Escobar Álvarez; J García Mata
Journal:  Clin Transl Oncol       Date:  2013-09-10       Impact factor: 3.405

5.  Safety and pharmacokinetic evaluation of repeated intravenous administration of palonosetron 0.75 mg in patients receiving highly or moderately emetogenic chemotherapy.

Authors:  Yosuke Ikari; Kentaro Ogata; Yuta Nakashima; Eiichi Sato; Michio Masaki; Hiroo Katsuya; Toshitaka Goto; Toshihiro Tanaka; Kenji Ishitsuka; Yasushi Takamatsu; Shuuji Hara; Kazuo Tamura
Journal:  Support Care Cancer       Date:  2014-03-04       Impact factor: 3.603

6.  Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in 5-day cisplatin-based germ cell tumor chemotherapy.

Authors:  I N Olver; P Grimison; M Chatfield; M R Stockler; G C Toner; V Gebski; R Harrup; C Underhill; G Kichenadasse; N Singhal; I D Davis; A Boland; A McDonald; D Thomson
Journal:  Support Care Cancer       Date:  2012-12-30       Impact factor: 3.603

7.  2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting.

Authors:  Lawrence H Einhorn; Bernardo Rapoport; Rudolph M Navari; Jørn Herrstedt; Mary J Brames
Journal:  Support Care Cancer       Date:  2016-11-04       Impact factor: 3.603

8.  Glycemic Status and Infection Risk in Nondiabetic Autologous Hematopoietic Cell Transplantation Recipients.

Authors:  Marilyn J Hammer; Gail D'Eramo Melkus; M Tish Knobf; Corey Casper; Jason Fletcher; Charles M Cleland
Journal:  Biol Res Nurs       Date:  2016-01-19       Impact factor: 2.522

9.  Phase II study of fosaprepitant + 5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: a Hoosier Cancer Research Network study.

Authors:  Nabil Adra; Costantine Albany; Mary J Brames; Somer Case-Eads; Cynthia S Johnson; Ziyue Liu; Christopher A Fausel; Timothy Breen; Nasser H Hanna; Ralph J Hauke; Joel Picus; Lawrence H Einhorn
Journal:  Support Care Cancer       Date:  2016-02-02       Impact factor: 3.603

Review 10.  Management of Chemotherapy Induced Nausea and Vomiting in Patients on Multiday Cisplatin Based Combination Chemotherapy.

Authors:  Praveen Ranganath; Lawrence Einhorn; Costantine Albany
Journal:  Biomed Res Int       Date:  2015-09-03       Impact factor: 3.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.